Brief: United Laboratories International Says Progress In Clinical Trial Of UBT251 Injection
25/03/2026 11:27
March 25 (Reuters) - United Laboratories International 3933.HK: PROGRESS IN CLINICAL TRIAL OF GROUP'S PRODUCT UBT251 INJECTION PHASE II CLINICAL TRIAL OF UBT251 INJECTION IN PATIENTS WITH TYPE 2 DIABETES ACHIEVED EXPECTED RESULTS Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million